Suppr超能文献

蛋白酶激活受体在健康和疾病中的作用。

Protease-activated receptors in health and disease.

机构信息

Department of Molecular Pathobiology, College of Dentistry, New York University, New York, New York.

Department of Neuroscience and Physiology and Neuroscience Institute, Grossman School of Medicine, New York University, New York, New York.

出版信息

Physiol Rev. 2023 Jan 1;103(1):717-785. doi: 10.1152/physrev.00044.2021. Epub 2022 Jul 28.

Abstract

Proteases are signaling molecules that specifically control cellular functions by cleaving protease-activated receptors (PARs). The four known PARs are members of the large family of G protein-coupled receptors. These transmembrane receptors control most physiological and pathological processes and are the target of a large proportion of therapeutic drugs. Signaling proteases include enzymes from the circulation; from immune, inflammatory epithelial, and cancer cells; as well as from commensal and pathogenic bacteria. Advances in our understanding of the structure and function of PARs provide insights into how diverse proteases activate these receptors to regulate physiological and pathological processes in most tissues and organ systems. The realization that proteases and PARs are key mediators of disease, coupled with advances in understanding the atomic level structure of PARs and their mechanisms of signaling in subcellular microdomains, has spurred the development of antagonists, some of which have advanced to the clinic. Herein we review the discovery, structure, and function of this receptor system, highlight the contribution of PARs to homeostatic control, and discuss the potential of PAR antagonists for the treatment of major diseases.

摘要

蛋白酶是一类信号分子,通过切割蛋白酶激活受体(PARs)特异性地控制细胞功能。已知的四个 PAR 是 G 蛋白偶联受体大家族的成员。这些跨膜受体控制着大多数生理和病理过程,也是很大一部分治疗药物的靶点。信号蛋白酶包括来自循环系统的酶;来自免疫、炎症上皮和癌细胞;以及来自共生和致病细菌的酶。我们对 PAR 结构和功能的理解的进展提供了深入了解不同的蛋白酶如何激活这些受体,从而调节大多数组织和器官系统中的生理和病理过程。认识到蛋白酶和 PAR 是疾病的关键介质,加上对 PAR 的原子水平结构及其在亚细胞微域中的信号转导机制的理解的进展,推动了拮抗剂的开发,其中一些已经进入临床阶段。本文综述了该受体系统的发现、结构和功能,强调了 PARs 对体内平衡控制的贡献,并讨论了 PAR 拮抗剂治疗主要疾病的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/9662810/e6f008b4cf15/prv-00044-2021r01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验